Who
Kristen Fortney
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, BioAge Labs.
In numbers
- Trades disclosed
- 7
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $8.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 17 Apr 2024
- Last trade
- 17 Feb 2026
- Last filed
- 19 Feb 2026
Companies traded
Activity over time
1 Jan – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 19 Feb 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Sold | $4.2M233,107 at $18.12 | filing |
| 13 Jan 2026filed 15 Jan 2026 | BIOA BioAge LabsBiotechnology | SEC FORM 4 Sold | $4.2M233,107 at $18.12 | filing |
| 18 Feb 2025filed 20 Feb 2025 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —530,000 at $0.00 | filing |
| 25 Sep 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —424,827 at $0.00 | filing |
| 17 Apr 2024filed 27 Sep 2024 | BIOA BioAge Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —708,044 at $0.00 | filing |
News
BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK) Head-To-Head AnalysisBIOA · themarketsdaily.com · 16 Oct 2026
0 headlines in the last 90 days name Kristen Fortney; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.